Price
No data yet.
Social Signal Score
Analyst Ratings
18 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jennifer L. Good
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 34
- Beta
- 1.05
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 133.15
Financials
Net Income
$-17.80MEBITDA
$-17.82MFree Cash Flow
$-17.55MEPS (diluted)
$-0.11Shares Outstanding (diluted)
156.60M+1147.6%Operating Expenses
$20.51MCash & Debt
$318.87MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-42.76M | $-0.29 |
| 2024 | $0.00 | $-47.91M | $-0.47 |
| 2023 | $0.00 | $-29.07M | $-0.29 |
| 2022 | $0.00 | $-29.15M | $-0.45 |
| 2021 | $0.00 | $-33.94M | $-1.49 |
| 2020 | $0.00 | $-32.76M | $-1.81 |
| 2019 | $0.00 | $-26.05M | $-1.46 |
| 2018 | $0.00 | $-20.55M | $-2.29 |
| 2017 | $0.00 | $-12.86M | $-1.43 |
| 2016 | $0.00 | $-11.09M | $-0.69 |
Valuation
TRVIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+20.00%Social Signal Score
Mentions (4)
- Newsseekingalpha.com·24d ago·Positive
Trevi Therapeutics, Inc. (TRVI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Trevi Therapeutics, Inc. (TRVI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·37d ago·Positive
Trevi Therapeutics to Participate in Upcoming September Conferences NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will particip…
View source ↗ - Newsglobenewswire.com·45d ago·Neutral
Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026 Professor Marlies Wijsenbeek will give an oral presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough
View source ↗ - Newsseekingalpha.com·51d ago·Neutral
…sion plans into non-IPF ILD and refractory chronic cough. Haduvio's positive Phase II data in both IPF and RCC, ongoing pivotal trials, and robust liquidity underpin TRVI's transition to a specialty pharma platform. TRVI's specialty-first strategy targets concentrated pulmonology networks, enabling efficient market entry and future expansion without large-scale commercial buildout.
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.13 per share
Typical surprise +10.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.11 vs $-0.11miss
- Tue, May 5$-0.09 vs $-0.07miss
- Tue, Mar 17$-0.06 vs $-0.10beat
- Thu, Nov 13$-0.08 vs $-0.10beat
- Thu, Aug 7$-0.09 vs $-0.10beat
- Thu, May 8$-0.09 vs $-0.13beat
Estimates and results for TRVI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TRVI officers and directors.
- Bought
- —
- Sold
- $1.1m
0 trades
11 trades
- Heffernan Michael Thomassold
- Heffernan Michael Thomassold
- Sciascia Thomassold
- Good Jennifer Lsold
- Simon Farrellsold
- Simon Farrellsold
- Good Jennifer Lsold
- Good Jennifer Lsold
89 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in TRVI.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.